ASKA Pharmaceutical : August 26 2022 Organizational and Personnel Changes of ASKA Pharmaceutical

Press Release

Organizational and Personnel Changes of ASKA Pharmaceutical

TOKYO, August 26, 2022 - ASKA Pharmaceutical Holdings Co., Ltd. (Headquarters: Minato-

ku, Tokyo/ President, Representative Director: Takashi Yamaguchi, hereinafter "ASKA") announced the following organizational and personnel changes of its subsidiary, ASKA Pharmaceutical Co., Ltd., effective October 1, 2022, respectively.

1. Organizational Change
   To reinforce the monitoring system for sales information provision activities, a new department independent from each division will be established.
2. • The "Sales Information Provision Supervisory Team" of Quality & Safety Assurance Division will be renamed the "Information service Supervisory Unit" and will become an independent organization.
3. Change of Corporate Officer's Responsibilities.

[New Responsibilities]

Corporate Officer, Director of Information service Supervisory Unit (Corporate Officer, In Charge of Audit and Legal Affairs & Regulatory

Kunihiro Gunji Compliance of ASKA Pharmaceutical Holdings Co., Ltd.) [Current Responsibilities]

Administrative Division * Seconded to ASKA Pharmaceutical Holdings Co., Ltd. (Corporate Officer, In Charge of Audit and Legal Affairs & Regulatory Compliance of ASKA Pharmaceutical Holdings Co., Ltd.)

3. Personnel Appointments

	[New Responsibilities]
	Assistant Division Director of Innovative Drug Discovery Division
	(Concurrently works in Portfolio Management Department)
Yasuhiro Tsukimi	[Current Responsibilities]
	Assistant Division Director of Innovative Drug Discovery Division
	Director of Drug Discovery Department
	(Concurrently works in Portfolio Management Department)
	[New Responsibilities]
	Assistant Division Director of Production Division
Kazuhiro Sasaki	Director of Pharmaceutical Technology Department
	[Current Responsibilities]
	Director of Pharmaceutical Technology Department, Production Division

1/2

	[New Responsibilities]
	Director of Drug Discovery Department, Innovative Drug Discovery Division
Masayuki	* concurrently continues as Manager of Drug Discovery Department
Yoshizawa	[Current Responsibilities]
	Manager of Drug Discovery Department, Innovative Drug Discovery
	Division
	[New Responsibilities]
	Director of Quality Assurance Department, Quality & Safety Assurance
Kenichi Tajima	Division * Quality Assurance Manager
[Current Responsibilities]
	Manager of Quality Assurance Department, Quality & Safety Assurance
	Division
	[New Responsibilities]
Chiaki Neuchi	Director of Quality Control Department, Iwaki Factory, Production Division
[Current Responsibilities]
	Manager of Manufacturing Department, Iwaki Factory, Production Division
	[New Responsibilities]
	Director of North Japan Sales Department, Sales Division
Takashi Ishimori	[Current Responsibilities]
	Manager of Sapporo Sales Office, North Japan Sales Department, Sales
	Division
	[New Responsibilities]
Akira Hasegawa	Director of West Japan Sales Department Region 2, Sales Division
[Current Responsibilities]
	Director of East Japan Sales Department Region 2, Sales Division
	[New Responsibilities]
	Director of East Japan Sales Department Region 2, Sales Division
Takeshi Okoshi	[Current Responsibilities]
	Manager of Saitama Sales Office, East Japan Sales Department Region 2,
	Sales Division

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: [phone]

Email: [e-mail]

2/2